Prediction of Medication-related Osteonecrosis of the Jaws Using Machine Learning Methods from Polymorphisms and Clinical Information

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2023 Jul 7

PMID 37415765

Authors

Seo-Yong Choi

Jin-Woo Kim

Sang-Hyeon Oh

Seunghyun Cheon

Jeong Yee

Sun-Jong Kim

Hye Sun Gwak

Jee-Eun Chung

Affiliations

Soon will be listed here.

Abstract

Objective: The purpose of this study was to evaluate the effect of () polymorphisms on the development of medication-related osteonecrosis of the jaws (MRONJ) in women with osteoporosis.

Methods: A total of 125 patients taking bisphosphonates was evaluated the relationship between MRONJ occurrence and single nucleotide polymorphisms (SNPs) of . Clinical information was collected, including current age, treatment duration, and comorbidity. Univariate and Multivariable regression analyzes were performed to evaluate the independent predictive factors for MRONJ occurrence. Predictive models were constructed using machine learning methods such as Lasso regression, Random forest (RF), and Support vector machine (SVM). The area under the receiver-operating curve (AUROC) was used to evaluate the performance of a binary classifier.

Result: Two SNPs of (rs4870056 and rs78177662) were significantly associated with MRONJ development. Patients with variant allele (A) of rs4870056 showed 2.45 times (95% CI, 1.03-5.87) the odds of MRONJ occurrence compared to those with wild-type homozygote (GG) after adjusting covariates. Additionally, carriers with variant allele (T) of rs78177662 had higher odds than those with wild-type homozygote (CC) (adjusted odds ratio (aOR), 2.64, 95% CI, 1.00-6.94). Among demographic variables, age ≥ 72 years (aOR, 3.98, 95% CI, 1.60-9.87) and bisphosphonate exposure ≥48 months (aOR, 3.16, 95% CI, 1.26-7.93) were also significant risk factors for MRONJ occurrence. AUROC values of machine learning methods ranged between 0.756-0.806 in the study.

Conclusion: Our study showed that the MRONJ occurrence was associated with polymorphisms in osteoporotic women.

Citing Articles

Genetic Background of Medication-Related Osteonecrosis of the Jaw: Current Evidence and Future Perspectives.

Bojtor B, Balla B, Vaszilko M, Szentpeteri S, Putz Z, Kosa J Int J Mol Sci. 2024; 25(19).

PMID: 39408816 PMC: 11477157. DOI: 10.3390/ijms251910488.

References

Rogers M . New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des. 2003; 9(32):2643-58. DOI: 10.2174/1381612033453640. View

Allen M, Burr D . Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008; 66(5):987-94. PMC: 2464292. DOI: 10.1016/j.joms.2008.01.038. View

Riggs B . The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000; 106(10):1203-4. PMC: 381441. DOI: 10.1172/JCI11468. View

Perzelova V, Sabol F, Vasilenko T, Novotny M, Kovac I, Slezak M . Pharmacological activation of estrogen receptors-α and -β differentially modulates keratinocyte differentiation with functional impact on wound healing. Int J Mol Med. 2015; 37(1):21-8. PMC: 4687436. DOI: 10.3892/ijmm.2015.2351. View

Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C . Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol. 2010; 31(2):464-9. PMC: 3074605. DOI: 10.1161/ATVBAHA.110.215087. View

Choe E, Rhee H, Lee S, Shin E, Oh S, Lee J . Metabolic Syndrome Prediction Using Machine Learning Models with Genetic and Clinical Information from a Nonobese Healthy Population. Genomics Inform. 2019; 16(4):e31. PMC: 6440667. DOI: 10.5808/GI.2018.16.4.e31. View

Cardemil C, Thomsen P, Wexell C . Jaw Bone Samples From Bisphosphonate-Treated Patients: A Pilot Cohort Study. Clin Implant Dent Relat Res. 2015; 17 Suppl 2:e679-91. DOI: 10.1111/cid.12307. View

Eertmans F, Dhooge W, de Wever O, Bracke M, Comhaire F, Kaufman J . Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line. J Cell Physiol. 2007; 212(3):583-90. DOI: 10.1002/jcp.21053. View

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

10.

Lamon-Fava S, Asztalos B, Howard T, Reboussin D, Horvath K, Schaefer E . Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. Clin Endocrinol (Oxf). 2009; 72(2):169-75. PMC: 2866027. DOI: 10.1111/j.1365-2265.2009.03644.x. View

11.

Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein R . The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010; 24(2):323-34. PMC: 2817608. DOI: 10.1210/me.2009-0354. View

12.

Drake M, Clarke B, Khosla S . Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9):1032-45. PMC: 2667901. DOI: 10.4065/83.9.1032. View

13.

Bedogni A, Fusco V, Agrillo A, Campisi G . Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012; 18(6):621-3. PMC: 3443365. DOI: 10.1111/j.1601-0825.2012.01903.x. View

14.

Harris H, Albert L, Leathurby Y, Malamas M, Mewshaw R, Miller C . Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology. 2003; 144(10):4241-9. DOI: 10.1210/en.2003-0550. View

15.

Rigatti S . Random Forest. J Insur Med. 2017; 47(1):31-39. DOI: 10.17849/insm-47-01-31-39.1. View

16.

Kitamura I, Ando F, Koda M, Okura T, Shimokata H . Effects of the interaction between lean tissue mass and estrogen receptor alpha gene polymorphism on bone mineral density in middle-aged and elderly Japanese. Bone. 2007; 40(6):1623-9. DOI: 10.1016/j.bone.2007.02.016. View

17.

Iizuka T, Miller S, Marks Jr S . Alveolar bone remodeling after tooth extraction in normal and osteopetrotic (ia) rats. J Oral Pathol Med. 1992; 21(4):150-5. DOI: 10.1111/j.1600-0714.1992.tb00092.x. View

18.

Piva F, Giulietti M, Burini A, Principato G . SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2011; 33(1):81-5. DOI: 10.1002/humu.21609. View

19.

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

20.

Wang C, Zhang Z, Zhang H, He J, Gu J, Hu W . Susceptibility genes for osteoporotic fracture in postmenopausal Chinese women. J Bone Miner Res. 2012; 27(12):2582-91. DOI: 10.1002/jbmr.1711. View